Your browser is no longer supported. Please, upgrade your browser.
ABBV AbbVie Inc. daily Stock Chart
AbbVie Inc.
IndexS&P 500 P/E16.85 EPS (ttm)3.88 Insider Own0.10% Shs Outstand1.59B Perf Week-1.84%
Market Cap104.23B Forward P/E10.10 EPS next Y6.48 Insider Trans-12.61% Shs Float1.59B Perf Month2.54%
Income6.31B PEG1.17 EPS next Q1.40 Inst Own70.80% Short Float2.05% Perf Quarter5.84%
Sales26.22B P/S3.98 EPS this Y16.20% Inst Trans1.26% Short Ratio5.42 Perf Half Y6.06%
Book/sh3.13 P/B20.91 EPS next Y17.28% ROA9.50% Target Price72.28 Perf Year9.63%
Cash/sh3.92 P/C16.68 EPS next 5Y14.45% ROE116.10% 52W Range55.06 - 68.12 Perf YTD4.50%
Dividend2.56 P/FCF38.01 EPS past 5Y10.90% ROI18.00% 52W High-3.94% Beta1.54
Dividend %3.91% Quick Ratio1.60 Sales past 5Y8.00% Gross Margin76.70% 52W Low18.85% ATR0.98
Employees30000 Current Ratio1.80 Sales Q/Q9.70% Oper. Margin36.30% RSI (14)46.79 Volatility1.46% 1.47%
OptionableYes Debt/Eq7.39 EPS Q/Q28.10% Profit Margin24.10% Rel Volume0.92 Prev Close65.58
ShortableYes LT Debt/Eq7.31 EarningsApr 27 BMO Payout60.20% Avg Volume6.03M Price65.44
Recom2.40 SMA20-0.90% SMA50-0.09% SMA2003.63% Volume5,534,169 Change-0.21%
Mar-22-17Upgrade Societe Generale Sell → Hold
Oct-31-16Downgrade Credit Suisse Outperform → Neutral
Oct-18-16Initiated Leerink Partners Mkt Perform $70
Sep-08-16Downgrade JP Morgan Overweight → Neutral
Sep-02-16Initiated Raymond James Outperform $82
Jun-08-16Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-06-16Initiated Societe Generale Sell $47
Mar-15-16Initiated Deutsche Bank Hold $63
Feb-23-16Upgrade Citigroup Neutral → Buy
Dec-01-15Downgrade Barclays Overweight → Equal Weight $73 → $72
Nov-02-15Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-23-15Reiterated UBS Buy $81 → $78
Sep-28-15Upgrade Citigroup Sell → Neutral
Jul-22-15Initiated Sun Trust Rbsn Humphrey Buy
Jun-17-15Initiated Piper Jaffray Overweight
Jun-08-15Reiterated Jefferies Buy $86 → $90
May-28-15Resumed Morgan Stanley Equal-Weight $72
May-27-15Resumed JP Morgan Overweight $75
Jan-06-15Reiterated UBS Buy $72 → $76
Nov-26-14Reiterated Argus Buy $65 → $85
May-22-17 08:42AM  The 3 Best Dividend Stocks in Arthritis Medication Motley Fool
May-20-17 01:23AM  [$$] AmerisourceBergen and AbbVie Top Barron's 500
May-19-17 09:30AM  The Zacks Analyst Blog Highlights: Boeing, AbbVie, UnitedHealth, Consolidated Edison and Cisco Zacks
08:00AM  AbbVie to Present at the Jefferies 2017 Global Healthcare Conference PR Newswire
May-18-17 07:00PM  For millions of Chinese with rare diseases, some relief in sight Reuters
04:37PM  AbbVie's Humira Loses Patent in Coherus' Petitions
03:50PM  Top 4 Marijuana Stocks to Watch for 2017 Investopedia
02:08PM  Biotech And Pharma Industry And Stock News Investor's Business Daily
12:48PM  New Stock Research Reports for Boeing, AbbVie and UnitedHealth Zacks
11:17AM  [$$] AbbVie: It's the Pipeline, Not the Coherus Ruling
09:23AM  AbbVie Down on Humira Patent Loss: Is More Damage in Store? Zacks
08:40AM  AbbVie, Inc. breached its 50 day moving average in a Bearish Manner : ABBV-US : May 18, 2017 Capital Cube
May-17-17 05:02PM  AbbVie Loses Key Humira Patent In Battle With Small-Cap Biotech Investor's Business Daily
05:00PM  AbbVie to Present Latest Clinical Study Results in Hematology and Solid Tumor Research at the 53rd American Society of Clinical Oncology (ASCO) Annual Meeting PR Newswire
02:55PM  Humira Ruling Is A 'Big Victory' For Coherus
12:10PM  Why This Humira Patent Loss Might Not Be What You Think 24/7 Wall St.
12:00PM  AbbVie Presents Pivotal Phase 3 Data on Investigational Treatment Elagolix at the World Congress on Endometriosis PR Newswire
10:53AM  AbbVie Stock Lower on Humira Patent Ruling
10:14AM  AbbVie: Losing Humira Patent Isn't The End
09:20AM  Morning Moves: Colgate, Target Climb; AbbVie Sinks; Disney Dips
07:35AM  US STOCKS-Futures slide as concerns over Trump spook investors Reuters
May-16-17 04:51PM  This Funds Picks Gained 200% In A Year And Why No One Knows About It Insider Monkey
03:42PM  3 Best Dividend Stocks in Biotech Motley Fool
May-15-17 06:47PM  Cramer's lightning round: This car company's not encouraging you to buy stock CNBC
10:30AM  AbbVie and J&J Present Positive Imbruvica Leukemia Data Zacks
May-14-17 05:00PM  IMBRUVICA® (ibrutinib) Pooled Outcomes Data from Three Phase 3 Studies Suggest Potential Clinical Efficacy in Patients with High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) PR Newswire
May-10-17 04:21PM  Investors Are Betting Big Against Marijuana Stock Insys Therapeutics -- Why They're Wrong Motley Fool
08:05AM  Why Gilead Sciences Stock Lagged Behind Other Biotechs in April Motley Fool
May-09-17 11:00AM  AbbVie Announces Positive Phase 2 Study Results for Upadacitinib (ABT-494), an Investigational JAK1-Selective Inhibitor, in Crohn's Disease PR Newswire
May-06-17 07:25AM  Which Big Pharma Is the Best Dividend Stock? Motley Fool
May-05-17 12:43PM  AbbVie to Present at the UBS Global Healthcare Conference PR Newswire
07:20AM  S&P Dividend Aristocrats: Which Stocks Make the List? Motley Fool
May-04-17 04:21PM  A Big, New Threat to Gilead Sciences Is Coming Motley Fool
09:00AM  AbbVie Demonstrates Leadership in Gastroenterology and Hepatology with New Data and Late-Breaking Studies to be Presented at Digestive Disease Week® PR Newswire
May-03-17 03:43PM  5 Things AbbVie Management Just Said That You'll Want to Know Motley Fool
May-02-17 06:24PM  Gilead Sciences Inc.'s Revenue and Earnings Continue to Fall on Declining HCV Sales Motley Fool
10:37AM  Venclexta Witnessed Healthy Demand Trends in 1Q17 Market Realist
09:08AM  AbbVie Is Focused on Label Expansion of Imbruvica in 2017 Market Realist
07:38AM  AbbVies Imbruvica Saw Solid Demand in 1Q17 Market Realist
May-01-17 12:37PM  MKM: Health care could buck the 'sell in May' trend CNBC Videos
12:05PM  Merck: Analysts Ratings and Recommendations Market Realist
10:39AM  Humira Witnessed Solid Demand Trends in 1Q17 Market Realist
10:08AM  Gilead Sciences: Fool Me Once
09:09AM  Analysts Recommendations for AbbVie in 2017 Market Realist
07:40AM  AbbVie Reported Robust Growth in Revenues in 1Q17 Market Realist
Apr-29-17 08:15AM  Edited Transcript of ABBV earnings conference call or presentation 27-Apr-17 1:00pm GMT Thomson Reuters StreetEvents
Apr-28-17 04:09PM  Vertex Big Winner In Biopharma Q1 As AbbVie, AstraZeneca Dip Investor's Business Daily
03:35PM  AbbVie Reports Humira Sales Growth in 1st Quarter
08:02AM  These 7 Drugmakers Relied on Price Hikes for 100% of Their Earnings Growth in 2016 Motley Fool
12:59AM  [$$] What Can Stop the Worlds Best Selling Drug? The Wall Street Journal
Apr-27-17 07:42PM  Oil's 'false tell' could set off domino effect CNBC Videos
07:01PM  Cramer: When Oil Falls, These Dominoes Get Hit
06:37PM  Cramer: How oil's 'false tell' could set off a market-cha... CNBC Videos
04:52PM  AbbVie (ABBV) Q1 Earnings Beat Estimates, Revenues Up Y/Y Zacks
04:48PM  AbbVie Flirts With Buy Point After Q1 Earnings, Sales Top Investor's Business Daily
12:57PM  [$$] What Can Stop the World's Best Selling Drug? The Wall Street Journal
12:07PM  Biopharma earnings bonanza CNBC Videos
11:00AM  AbbVie Posts Solid First Quarter Boosted by Humira Morningstar
09:27AM  AbbVie (ABBV) Beats Earnings and Revenue in Q1 Zacks
07:51AM  AbbVie stock surges 1.5% after first-quarter profit, revenue beats MarketWatch
07:47AM  Drugmaker AbbVie's profit rises 26.4 pct Reuters
07:46AM  AbbVie tops Street 1Q forecasts Associated Press
07:38AM  AbbVie Reports First-Quarter 2017 Financial Results PR Newswire
06:35AM  Market Recon: The Tax Reform Is Just Ordinary Negotiation on Steroids
Apr-26-17 08:04AM  Pharma Stocks Q1 Earnings Roster for Apr 27: CELG, ABBV, BMY Zacks
Apr-25-17 08:00AM  Aquinnah Pharmaceuticals Receives $10 Million Investment from Pfizer and AbbVie to Research Breakthrough Approach to Neurodegenerative Disease PR Newswire
Apr-23-17 03:02PM  3 Dividend Stocks That Investors Should Love Motley Fool
Apr-22-17 09:48AM  Better Buy: AbbVie Inc. vs. Pfizer Motley Fool
Apr-21-17 06:49PM  Cramer's lightning round: This drug stock is simply not good enough for your portfolio CNBC
11:25AM  AbbVie (ABBV) Presents Positive Data on HCV Combination Drug Zacks
09:57AM  What's in Store for AbbVie (ABBV) this Earnings Season? Zacks
08:15AM  Blog Coverage AbbVie's HCV Regimen Achieves 99% Cure Rate in Phase III Study Accesswire
08:00AM  AbbVie to Present at the Deutsche Bank 42nd Annual Health Care Conference PR Newswire
01:00AM  Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR(12) Rates in Challenging to Treat Genotype 3 Chronic Hepatitis C PR Newswire
Apr-20-17 02:46PM  AbbVie, Inc. Value Analysis (NYSE:ABBV) : April 20, 2017 Capital Cube
02:42PM  Failure Of Abbvie's Cancer Drug Hasn't Hurt The Stock
01:21PM  AbbVie's PARP Inhibitor Comes Up Empty Motley Fool
09:53AM  AbbVie's (ABBV) Cancer Candidate Fails in Phase III Studies Zacks
07:30AM  AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved 99 Percent SVR(12) Rate in Chronic Hepatitis C Patients with Compensated Cirrhosis PR Newswire
Apr-19-17 07:13PM  AbbVie cancer drug fails two late-stage trials Reuters
06:17PM  AbbVie cancer drug fails two late-stage trials Reuters
08:31AM  AbbVie, Inc. breached its 50 day moving average in a Bearish Manner : ABBV-US : April 19, 2017 Capital Cube
Apr-18-17 04:01PM  Dow's Johnson & Johnson Highlights 'Multiple Issues' For Drugs, Biotechs Investor's Business Daily
03:14PM  Is AbbVie a Great Dividend Stock for Your Portfolio? Motley Fool
01:34PM  The Better Big Pharma Stock: AbbVie or Gilead?
11:41AM  High-Yield Healthcare Investments You Can Buy Right Now Motley Fool
Apr-17-17 04:13PM  Can Lilly Survive Rheumatoid Arthritis Flop With Breast Cancer Drug? Investor's Business Daily
11:12AM  AbbVie, Inc. : ABBV-US: Dividend Analysis : April 13th, 2017 (record date) : By the numbers : April 17, 2017 Capital Cube
09:40AM  Lilly and Incyte's Loss Is AbbVie and Regeneron's Gain Motley Fool
Apr-15-17 12:23AM  [$$] As Drug Prices Fall, These Stocks Could Rise
Apr-14-17 12:35PM  ABB Stock Trades Ex-Dividend Tuesday Investopedia
08:04AM  AbbVie Inc.: The Bear Case From a Bull Motley Fool
Apr-10-17 10:48AM  AbbVie's Elagolix Meets Primary Endpoint in Phase II Study Zacks
Apr-09-17 07:22AM  5 Pharmaceutical Stocks With the Most Reliable Dividends Motley Fool
Apr-08-17 06:41AM  3 Cheap High-Yield Dividend Stocks to Grow Your Retirement Portfolio Motley Fool
Apr-07-17 09:56AM  AbbVie Stock Trades Ex-Dividend Tuesday Investopedia
08:00AM  AbbVie Announces Positive Phase 2b Data Demonstrating Investigational Medicine Elagolix Significantly Reduced Heavy Menstrual Bleeding in Women with Uterine Fibroids PR Newswire
Apr-06-17 10:48AM  3 Top Big Pharma Stocks to Buy Now Motley Fool
08:00AM  AbbVie to Host First-Quarter Earnings Conference Call PR Newswire
Apr-05-17 04:21PM  Better Buy: AbbVie Inc. vs. GlaxoSmithKline Motley Fool
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus(HIV)-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a subcutaneous treatment for relapsing forms of multiple sclerosis. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has collaboration agreements with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; and M2Gen. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CHASE WILLIAM JEVP, Chief Financial OfficerMay 18Option Exercise28.6238,3001,095,994221,843May 19 05:01 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMay 18Sale65.3538,3002,502,905183,543May 19 05:01 PM
ALBAN CARLOSEVP, Commercial OperationsMay 04Sale67.0043,0002,881,000114,745May 08 05:13 PM
AbbVie Inc.10% OwnerMar 28Sale22.50450,00010,125,0001,190,473Mar 30 05:48 PM
Schumacher Laura JExecutive Vice PresidentMar 10Sale65.2640,0002,610,257107,825Mar 10 05:22 PM
Michael Robert A.VP, ControllerMar 10Sale65.295,132335,06816,706Mar 10 05:22 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesMar 10Sale65.2922,4511,465,82626,078Mar 10 05:21 PM
GONZALEZ RICHARD AChairman of the Board and CEOMar 08Option Exercise27.9572,0162,012,610422,763Mar 10 05:20 PM
GONZALEZ RICHARD AChairman of the Board and CEOMar 08Sale64.2572,0164,627,028350,747Mar 10 05:20 PM
HURWICH THOMAS A.VP, ControllerFeb 28Sale61.892,311143,03167,276Mar 02 06:12 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 02Option Exercise27.292,40065,4965,431Feb 03 05:21 PM
CHASE WILLIAM JEVP, Chief Financial OfficerDec 02Option Exercise27.296,600180,114178,970Dec 02 05:08 PM
CHASE WILLIAM JEVP, Chief Financial OfficerDec 02Sale59.196,600390,654172,370Dec 02 05:08 PM
HURWICH THOMAS A.VP, ControllerNov 16Option Exercise28.863,10089,47564,549Nov 18 05:39 PM
HURWICH THOMAS A.VP, ControllerNov 16Sale62.003,100192,20061,449Nov 18 05:39 PM
Schumacher Laura JExecutive Vice PresidentSep 07Sale65.0050,0003,250,000144,138Sep 09 05:38 PM
Schumacher Laura JExecutive Vice PresidentJun 24Option Exercise27.62186,1065,140,971380,244Jun 28 05:47 PM
Schumacher Laura JExecutive Vice PresidentJun 24Sale60.03186,10611,171,173194,138Jun 28 05:47 PM
GONZALEZ RICHARD AChairman of the Board and CEOJun 02Sale63.82285,95318,249,712338,421Jun 03 05:26 PM